FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986408034> ?p ?o ?g. }

• W1986408034 endingPage "954" @default.
• W1986408034 startingPage "947" @default.
• W1986408034 abstract "Purpose To evaluate the combination of radiation and an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in preclinical models of human non-small cell lung cancer. Methods and Materials Sensitivity to an EGFR TKI (gefitinib) or radiation was assessed using proliferation assays and clonogenic survival assays. Effects on receptor signal transduction pathways (pEGFR, pAKT, pMAPK) and apoptosis (percentage of cleaved PARP Poly (ADP-ribose) polymerase (PARP)) were assessed by Western blotting. Radiation-induced DNA damage was assessed by γH2AX immunofluorescence. Established (≥100 mm3) EGFR-mutated (HCC287) or EGFR wild-type (A549) subcutaneous xenografts were treated with radiation (10 Gy, day 1) or gefitinib (50 mg/kg, orally, on days 1-3) or both. Results In non-small cell lung cancer (NSCLC) cell lines with activating EGFR mutations (PC9 or HCC827), gefitinib treatment markedly reduced pEGFR, pAKT, and pMAPK levels and was associated with an increase in cleaved PARP but not in γH2AX foci. Radiation treatment increased the mean number of γH2AX foci per cell but did not significantly affect EGFR signaling. In contrast, NSCLC cell lines with EGFR T790M (H1975) or wild-type EGFR (A549) were insensitive to gefitinib treatment. The combination of gefitinib and radiation treatment in cell culture produced additive cell killing with no evidence of synergy. In xenograft models, a short course of gefitinib (3 days) did not significantly increase the activity of radiation treatment in wild-type EGFR (A549) tumors (P=.27), whereas this combination markedly increased the activity of radiation (P<.001) or gefitinib alone (P=.002) in EGFR-mutated HCC827 tumors, producing sustained tumor regressions. Conclusions Gefitinib treatment increases clonogenic cell killing by radiation but only in cell lines sensitive to gefitinib alone. Our data suggest additive rather than synergistic interactions between gefitinib and radiation and that a combination of short-course gefitinib and high-dose/-fraction radiation may have the greatest potential against the subsets of lung cancers harboring activating mutations in the EGFR gene. To evaluate the combination of radiation and an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in preclinical models of human non-small cell lung cancer. Sensitivity to an EGFR TKI (gefitinib) or radiation was assessed using proliferation assays and clonogenic survival assays. Effects on receptor signal transduction pathways (pEGFR, pAKT, pMAPK) and apoptosis (percentage of cleaved PARP Poly (ADP-ribose) polymerase (PARP)) were assessed by Western blotting. Radiation-induced DNA damage was assessed by γH2AX immunofluorescence. Established (≥100 mm3) EGFR-mutated (HCC287) or EGFR wild-type (A549) subcutaneous xenografts were treated with radiation (10 Gy, day 1) or gefitinib (50 mg/kg, orally, on days 1-3) or both. In non-small cell lung cancer (NSCLC) cell lines with activating EGFR mutations (PC9 or HCC827), gefitinib treatment markedly reduced pEGFR, pAKT, and pMAPK levels and was associated with an increase in cleaved PARP but not in γH2AX foci. Radiation treatment increased the mean number of γH2AX foci per cell but did not significantly affect EGFR signaling. In contrast, NSCLC cell lines with EGFR T790M (H1975) or wild-type EGFR (A549) were insensitive to gefitinib treatment. The combination of gefitinib and radiation treatment in cell culture produced additive cell killing with no evidence of synergy. In xenograft models, a short course of gefitinib (3 days) did not significantly increase the activity of radiation treatment in wild-type EGFR (A549) tumors (P=.27), whereas this combination markedly increased the activity of radiation (P<.001) or gefitinib alone (P=.002) in EGFR-mutated HCC827 tumors, producing sustained tumor regressions. Gefitinib treatment increases clonogenic cell killing by radiation but only in cell lines sensitive to gefitinib alone. Our data suggest additive rather than synergistic interactions between gefitinib and radiation and that a combination of short-course gefitinib and high-dose/-fraction radiation may have the greatest potential against the subsets of lung cancers harboring activating mutations in the EGFR gene." @default.
• W1986408034 created "2016-06-24" @default.
• W1986408034 creator A5023359626 @default.
• W1986408034 creator A5049916487 @default.
• W1986408034 creator A5061825962 @default.
• W1986408034 creator A5069480605 @default.
• W1986408034 creator A5069898333 @default.
• W1986408034 date "2014-03-01" @default.
• W1986408034 modified "2023-09-28" @default.
• W1986408034 title "Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer" @default.
• W1986408034 cites W1602534286 @default.
• W1986408034 cites W1964098504 @default.
• W1986408034 cites W1968366677 @default.
• W1986408034 cites W1975509166 @default.
• W1986408034 cites W1979332174 @default.
• W1986408034 cites W1979388665 @default.
• W1986408034 cites W1983787599 @default.
• W1986408034 cites W1994861590 @default.
• W1986408034 cites W2016710415 @default.
• W1986408034 cites W2022417639 @default.
• W1986408034 cites W2022942989 @default.
• W1986408034 cites W2027630134 @default.
• W1986408034 cites W2041992600 @default.
• W1986408034 cites W2043696829 @default.
• W1986408034 cites W2056960574 @default.
• W1986408034 cites W2073802604 @default.
• W1986408034 cites W2106787323 @default.
• W1986408034 cites W2114464493 @default.
• W1986408034 cites W2115785123 @default.
• W1986408034 cites W2118113452 @default.
• W1986408034 cites W2119831956 @default.
• W1986408034 cites W2132834292 @default.
• W1986408034 cites W2134807701 @default.
• W1986408034 cites W2139236349 @default.
• W1986408034 cites W2142578088 @default.
• W1986408034 cites W2153243769 @default.
• W1986408034 cites W2154385453 @default.
• W1986408034 cites W2161821474 @default.
• W1986408034 cites W2166630278 @default.
• W1986408034 cites W2171253082 @default.
• W1986408034 doi "https://doi.org/10.1016/j.ijrobp.2013.12.038" @default.
• W1986408034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24606853" @default.
• W1986408034 hasPublicationYear "2014" @default.
• W1986408034 type Work @default.
• W1986408034 sameAs 1986408034 @default.
• W1986408034 citedByCount "25" @default.
• W1986408034 countsByYear W19864080342015 @default.
• W1986408034 countsByYear W19864080342016 @default.
• W1986408034 countsByYear W19864080342017 @default.
• W1986408034 countsByYear W19864080342018 @default.
• W1986408034 countsByYear W19864080342020 @default.
• W1986408034 countsByYear W19864080342021 @default.
• W1986408034 countsByYear W19864080342023 @default.
• W1986408034 crossrefType "journal-article" @default.
• W1986408034 hasAuthorship W1986408034A5023359626 @default.
• W1986408034 hasAuthorship W1986408034A5049916487 @default.
• W1986408034 hasAuthorship W1986408034A5061825962 @default.
• W1986408034 hasAuthorship W1986408034A5069480605 @default.
• W1986408034 hasAuthorship W1986408034A5069898333 @default.
• W1986408034 hasConcept C117262875 @default.
• W1986408034 hasConcept C121608353 @default.
• W1986408034 hasConcept C126322002 @default.
• W1986408034 hasConcept C143998085 @default.
• W1986408034 hasConcept C190283241 @default.
• W1986408034 hasConcept C2776256026 @default.
• W1986408034 hasConcept C2779438470 @default.
• W1986408034 hasConcept C2780580887 @default.
• W1986408034 hasConcept C502942594 @default.
• W1986408034 hasConcept C509974204 @default.
• W1986408034 hasConcept C54355233 @default.
• W1986408034 hasConcept C55493867 @default.
• W1986408034 hasConcept C62112901 @default.
• W1986408034 hasConcept C71924100 @default.
• W1986408034 hasConcept C86803240 @default.
• W1986408034 hasConceptScore W1986408034C117262875 @default.
• W1986408034 hasConceptScore W1986408034C121608353 @default.
• W1986408034 hasConceptScore W1986408034C126322002 @default.
• W1986408034 hasConceptScore W1986408034C143998085 @default.
• W1986408034 hasConceptScore W1986408034C190283241 @default.
• W1986408034 hasConceptScore W1986408034C2776256026 @default.
• W1986408034 hasConceptScore W1986408034C2779438470 @default.
• W1986408034 hasConceptScore W1986408034C2780580887 @default.
• W1986408034 hasConceptScore W1986408034C502942594 @default.
• W1986408034 hasConceptScore W1986408034C509974204 @default.
• W1986408034 hasConceptScore W1986408034C54355233 @default.
• W1986408034 hasConceptScore W1986408034C55493867 @default.
• W1986408034 hasConceptScore W1986408034C62112901 @default.
• W1986408034 hasConceptScore W1986408034C71924100 @default.
• W1986408034 hasConceptScore W1986408034C86803240 @default.
• W1986408034 hasIssue "4" @default.
• W1986408034 hasLocation W19864080341 @default.
• W1986408034 hasLocation W19864080342 @default.
• W1986408034 hasOpenAccess W1986408034 @default.
• W1986408034 hasPrimaryLocation W19864080341 @default.
• W1986408034 hasRelatedWork W1976268611 @default.
• W1986408034 hasRelatedWork W1987542515 @default.
• W1986408034 hasRelatedWork W2005973176 @default.
• W1986408034 hasRelatedWork W2044653442 @default.

• next